Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

NCT05111912 on ClinicalTrials.gov · last registry update 2023-08-21

Finished 16 November 2022, after enrolling 206 people. Primary outcome, as filed: Percentage change in participants body weight (%) from the Baseline. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Sponsor type: Industry
Enrollment: 206
Started: 2021-11-30
Primary completion: 2022-11-16 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage change in participants body weight (%) from the Baseline

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.